Safety of proton pump inhibitor exposure

Gastroenterology

Volumn 139, Issue 4, 2010, Pages 1115-1127

  Yang, Yu Xiao ^a   Metz, David C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acid Suppressive Therapy; Drug Safety; Side Effects

Indexed keywords

ACETYLSALICYLIC ACID; BENATOPRAZOLE; CALCIUM; CLOPIDOGREL; CYANOCOBALAMIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; ESOMEPRAZOLE; GASTRIN; GASTRIN DERIVATIVE; ILAPRAZOLE; IRON; LANSOPRAZOLE; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE;

ACHLORHYDRIA; ADVERSE OUTCOME; ATROPHIC GASTRITIS; BONE DENSITY; CALCIUM ABSORPTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLORECTAL CANCER; CYANOCOBALAMIN DEFICIENCY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HIP FRACTURE; HUMAN; HYPOMAGNESEMIA; INFECTION RISK; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; IRON ABSORPTION; NONHUMAN; OSTEOPOROSIS; PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH PH; VITAMIN BLOOD LEVEL; ZOLLINGER ELLISON SYNDROME; ANALOGS AND DERIVATIVES; ANIMAL; BONE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; NEOPLASM;

ANIMALS; BONE AND BONES; CALCIUM; DRUG INTERACTIONS; HUMANS; IRON; MAGNESIUM; NEOPLASMS; PROTON PUMP INHIBITORS; TICLOPIDINE; VITAMIN B 12;

EID: 77957327211     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.08.023     Document Type: Review

References (152)

1. D. Metz Proton pump inhibitor therapy: safety issues C.W. Howden, Advances in digestive disease 2007 AGA Institute Press Bethesda, MD 3 14
2. S. Shi, and U. Klotz Proton pump inhibitors: an update of their clinical use and pharmacokinetics Eur J Clin Pharmacol 64 2008 935 951
3. R.S. Sandler, J.E. Everhart, and M. Donowitz The burden of selected digestive diseases in the United States Gastroenterology 122 2002 1500 1511
4. D.C. Metz, J.M. Inadomi, and C.W. Howden On-demand therapy for gastroesophageal reflux disease Am J Gastroenterol 102 2007 642 653
5. T.B. Nealis, and C.W. Howden Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther 15 2008 536 542
6. A.S. Raghunath, C. O'Morain, and R.C. McLoughlin Review article: the long-term use of proton-pump inhibitors Aliment Pharmacol Ther 22 Suppl 1 2005 55 63
7. R.T. Jensen Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas Basic Clin Pharmacol Toxicol 98 2006 4 19
8. J.P. Galmiche, S. Bruley Des Varannes, and P. Ducrotte Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 2004 655 662
9. R.H. Hunt Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 Aliment Pharmacol Ther 22 Suppl 3 2005 10 19
10. R.H. Hunt, D. Armstrong, and C. James Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers Am J Gastroenterol 100 2005 1949 1956
11. R.H. Hunt, D. Armstrong, and M. Yaghoobi Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z Aliment Pharmacol Ther 28 2008 187 199
12. P.O. Katz, J.M. Scheiman, and A.N. Barkun Review article: acid-related diseasewhat are the unmet clinical needs? Aliment Pharmacol Ther 23 Suppl 2 2006 9 22
13. D.C. Metz, M. Vakily, and T. Dixit Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy Aliment Pharmacol Ther 29 2009 928 937
14. D.A. Peura, D.C. Metz, and A.H. Dabholkar Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience Aliment Pharmacol Ther 30 2009 1010 1021
15. C. Scarpignato, and I. Pelosini Review article: the opportunities and benefits of extended acid suppression Aliment Pharmacol Ther 23 Suppl 2 2006 23 34
16. J.M. Shin, and G. Sachs Pharmacology of proton pump inhibitors Curr Gastroenterol Rep 10 2008 528 534
17. G. Sachs, J.M. Shin, and C. Briving The pharmacology of the gastric acid pump: the H+,K+ ATPase Annu Rev Pharmacol Toxicol 35 1995 277 305
18. G. Sachs, J.M. Shin, and C.W. Howden Review article: the clinical pharmacology of proton pump inhibitors Aliment Pharmacol Ther 23 Suppl 2 2006 2 8
19. C.W. Howden, D.C. Metz, and B. Hunt Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h Aliment Pharmacol Ther 23 2006 975 984
20. T.O.G. Kovacs, C.Q. Lee, and Y.L. Chiu Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis Aliment Pharmacol Ther 20 2004 883 889
21. R.D. Lee, M. Vakily, and D. Mulford Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitorevidence for dosing flexibility Aliment Pharmacol Ther 29 2009 824 833
22. D.C. Metz, J.W. Devlin, and M. Vakily Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion Pharmacotherapy 28 2008 301 307
23. D.C. Metz, P.B. Miner, and D.M. Heuman Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease Aliment Pharmacol Ther 22 2005 813 821
24. K. Rzeszutek, F. Sarraf, and J.E. Davies Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth J Craniofac Surg 14 2003 301 307
25. J. Tuukkanen, and H.K. Vaananen Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro Calcif Tissue Int 38 1986 123 125
26. P. Miner Jr, P.O. Katz, and Y. Chen Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2003 2616 2620
27. N.G.M. Hunfeld, W.P. Geus, and E.J. Kuipers Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors Aliment Pharmacol Ther 25 2007 39 46
28. E.J. Kuipers, L. Lundell, and E.C. Klinkenberg-Knol Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication N Engl J Med 334 1996 1018 1022
29. J.W. Freston, M. Hisada, and D.A. Peura The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis Aliment Pharmacol Ther 29 2009 1249 1260
30. R. Lamberts, G. Brunner, and E. Solcia Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa Digestion 64 2001 205 213
31. R. Fass, M. Shapiro, and R. Dekel Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux diseasewhere next? Aliment Pharmacol Ther 22 2005 79 94
32. S.A. Conrad, A. Gabrielli, and B. Margolis Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients Crit Care Med 33 2005 760 765
33. D. Castell, R. Bagin, and B. Goldlust Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease Aliment Pharmacol Ther 21 2005 1467 1474
34. C.W. Howden, E.D. Ballard, and F.K. Koch Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD J Clin Gastroenterol 43 2009 323 326
35. C.W. Howden Review article: immediate-release proton-pump inhibitor therapypotential advantages Aliment Pharmacol Ther 22 Suppl 3 2005 25 30
36. D.A. Johnson, S.B. Benjamin, and N.B. Vakil Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety [Erratum appears in Am J Gastroenterol 2001 Mar;96(3):942] Am J Gastroenterol 96 2001 27 34
37. N.B. Vakil, R. Shaker, and D.A. Johnson The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety Aliment Pharmacol Ther 15 2001 927 935
38. A. Abelo, T.B. Andersson, and M. Antonsson Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes Drug Metab Dispos 28 2000 966 972 (Pubitemid 30612617)
39. J.R. Saltzman, J.A. Kemp, and B.B. Golner Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption.[see comment] J Am Coll Nutr 13 1994 584 591
40. A. Doscherholmen, and W.R. Swaim Impaired assimilation of egg Co 57 vitamin B 12 in patients with hypochlorhydria and achlorhydria and after gastric resection Gastroenterology 64 1973 913 919
41. H.P. Festen Intrinsic factor secretion and cobalamin absorption Physiology and pathophysiology in the gastrointestinal tract Scand J Gastroenterol Suppl 188 1991 1 7
42. S.K. Dutta Vitamin B12 malabsorption and omeprazole therapy J Am Coll Nutr 13 1994 544 545 [comment][erratum appears in J Am Coll Nutr 1995 Jun;14(3):218]
43. C.E. King, J. Leibach, and P.P. Toskes Clinically significant vitamin B12 deficiency secondary to malabsorption of protein-bound vitamin B12 Dig Dis Sci 24 1979 397 402
44. P.M. Suter, B.B. Golner, and B.R. Goldin Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis Gastroenterology 101 1991 1039 1045
45. J. Thorens, F. Froehlich, and W. Schwizer Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study Gut 39 1996 54 59
46. S.P. Pereira, N. Gainsborough, and R.H. Dowling Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly Aliment Pharmacol Ther 12 1998 99 104
47. S.P. Marcuard, L. Albernaz, and P.G. Khazanie Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12) Ann Intern Med 120 1994 211 215 [see comment]
48. B.E. Schenk, H.P. Festen, and E.J. Kuipers Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin Aliment Pharmacol Ther 10 1996 541 545
49. E. Kittang, E. Aadland, and H. Schjonsby The effect of omeprazole on gastric acidity and the absorption of liver cobalamins Scand J Gastroenterol 22 1987 156 160
50. R.J. Valuck, and J.M. Ruscin A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults J Clin Epidemiol 57 2004 422 428
51. B. Termanini, F. Gibril, and V.E. Sutliff Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome Am J Med 104 1998 422 430 (Pubitemid 28274845)
52. W.P. den Elzen, Y. Groeneveld, and W. de Ruijter Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals Aliment Pharmacol Ther 27 2008 491 497
53. R.A. Dhonukshe-Rutten, M. Lips, and N. de Jong Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men J Nutr 133 2003 801 807
54. E.T. Champagne Low gastric hydrochloric acid secretion and mineral bioavailability Adv Exp Med Biol 249 1989 173 184
55. M.S. Sheikh, C.A. Santa Ana, and M.J. Nicar Gastrointestinal absorption of calcium from milk and calcium salts N Engl J Med 317 1987 532 536
56. R.R. Recker Calcium absorption and achlorhydria N Engl J Med 313 1985 70 73
57. B.E. Nordin Calcium and osteoporosis Nutrition 13 1997 664 686
58. O. Chonan, R. Takahashi, and H. Yasui Effect of L-lactic acid on calcium absorption in rats fed omeprazole J Nutr Sci Vitaminol 44 1998 473 481 (Pubitemid 28370958)
59. P. Ivanovich, H. Fellows, and C. Rich The absorption of calcium carbonate Ann Intern Med 66 1967 917 923
60. N.A. Merriman, M.E. Putt, and D.C. Metz Hip fracture risk in patients with a diagnosis of pernicious anemia Gastroenterology 138 2010 1330 1337
61. J.B. Goerss, C.H. Kim, and E.J. Atkinson Risk of fractures in patients with pernicious anemia J Bone Miner Res 7 1992 573 579
62. L. Nilas, C. Christiansen, and J. Christiansen Regulation of vitamin D and calcium metabolism after gastrectomy Gut 26 1985 252 257
63. G. Graziani, G. Como, and S. Badalamenti Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects Nephrol Dial Transplant 10 1995 1376 1380
64. G. Graziani, S. Badalamenti, and G. Como Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload Role of gastric acid secretion Nephron 91 2002 474 479
65. P. Hardy, A. Sechet, and C. Hottelart Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis Artif Organs 22 1998 569 573
66. M.B. O'Connell, D.M. Madden, and A.M. Murray Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial Am J Med 118 2005 778 781
67. C. Serfaty-Lacrosniere, R.J. Wood, and D. Voytko Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans J Am Coll Nutr 14 1995 364 368
68. R.P. Heaney Factors influencing the measurement of bioavailability, taking calcium as a model J Nutr 131 2001 1344S 1348S
69. W. Bezwoda, R. Charlton, and T. Bothwell The importance of gastric hydrochloric acid in the absorption of nonheme food iron J Lab Clin Med 92 1978 108 116
70. C.A. Stewart, B. Termanini, and V.E. Sutliff Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy Aliment Pharmacol Ther 12 1998 83 98 (Pubitemid 28057410)
71. C. Hutchinson, C.A. Geissler, and J.J. Powell Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis Gut 56 2007 1291 1295
72. M. Epstein, S. McGrath, and F. Law Proton-pump inhibitors and hypomagnesemic hypoparathyroidism N Engl J Med 355 2006 1834 1836
73. T. Cundy, and A. Dissanayake Severe hypomagnesaemia in long-term users of proton-pump inhibitors Clin Endocrinol 69 2008 338 341
74. N. Shabajee, E.J. Lamb, and I. Sturgess Omeprazole and refractory hypomagnesaemia BMJ 337 2008 a425
75. M.A.C. Broeren, E.A.M. Geerdink, and H.L. Vader Hypomagnesemia induced by several proton pump inhibitors Ann Intern Med 151 2009 755 756
76. J.D. MacKay, and P.T. Bladon Hypomagnesemia due to proton pump inhibitor therapy: a clinical case series Q J Med 103 6 2010 387 395
77. G.A. Quamme Recent developments in intestinal magnesium absorption Curr Opin Gastroenterol 24 2008 230 235
78. K.P. Schlingmann, S. Weber, and M. Peters Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family Nat Genet 31 2002 166 170
79. A. Miyake, S. Mochizuki, and H. Kawashima Characterization of cloned human cholecystokinin-B receptor as a gastrin receptor Biochem Pharmacol 47 1994 1339 1343
80. Y.S. Guo, and C.M. Townsend Jr Role of gastrointestinal hormones in pancreatic cancer J Hepatobiliary Pancreat Surg 7 2000 276 285
81. D.F. McWilliams, S.A. Watson, and D.M. Crosbee Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines Gut 42 1998 795 798
82. J.P. Smith, W.B. Stanley, and M.F. Verderame The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer Pancreas 29 2004 271 277
83. C. Seva, C. Dickinson, and T. Yamada Growth-promoting effects of glycine-extended progastrin Science 265 1994 410 412
84. M.L. Kochman, J. DelValle, and C.J. Dickinson Post-translation processing of gastrin in neoplastic human colonic tissues Biochem Biophys Res Commun 189 1992 1165 1169
85. Min-/+Mouse model of familial adenomatous polyposis Cancer Res 61 2001 625 631
86. C.M. Thorburn, G.D. Friedman, and C.J. Dickinson Gastrin and colorectal cancer: a prospective study Gastroenterology 115 1998 275 280
87. Y.X. Yang, S. Hennessy, and K. Propert Chronic proton pump inhibitor therapy and the risk of colorectal cancer Gastroenterology 133 2007 748 754
88. E.M. van Soest, L.G.M. van Rossum, and J.P. Dieleman Proton pump inhibitors and the risk of colorectal cancer Am J Gastroenterol 103 2008 966 973
89. D.J. Robertson, H. Larsson, and S. Friis Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study Gastroenterology 133 2007 755 760
90. E.C. Klinkenberg-Knol, F. Nelis, and J. Dent Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa Gastroenterology 118 2000 661 669
91. F. Islami, F. Kamangar, and P. Boffetta Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions Am J Gastroenterol 104 2009 2646 2648
92. D.M. Nguyen, H.B. El-Serag, and L. Henderson Medication usage and the risk of neoplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 7 2009 1299 1304
93. X.-Q. Li, T.B. Andersson, and M. Ahlstrom Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 2004 821 827
94. T. Simon, C. Verstuyft, and M. Mary-Krause French Registry of Acute STE, Non STEMII Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
95. M. Gilard, B. Arnaud, and J.-C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
96. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
97. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
98. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
99. W.A. Ray, K.T. Murray, and M.R. Griffin Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study Ann Intern Med 152 2010 337 345
100. J.H. Wandall Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245 Gut 33 1992 617 621
101. R.J.F. Laheij, M.C.J.M. Sturkenboom, and R.-J. Hassing Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs JAMA 292 2004 1955 1960 [see comment]
102. S.E. Gulmez, A. Holm, and H. Frederiksen Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study Arch Intern Med 167 2007 950 955
103. M. Sarkar, S. Hennessy, and Y.X. Yang Proton-pump inhibitor use and the risk for community-acquired pneumonia Ann Intern Med 149 2008 391 398
104. A. Dublin, R.L. Walker, and M.L. Kackson Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study Pharmacoepidemiol Drug Saf 19 2010 792 802
105. S. Dial, J.A.C. Delaney, and V. Schneider Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy CMAJ 175 2006 745 748
106. S. Dial, J.A.C. Delaney, and A.N. Barkun Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease JAMA 294 2005 2989 2995
107. J. Leonard, J.K. Marshall, and P. Moayyedi Systematic review of the risk of enteric infection in patients taking acid suppression Am J Gastroenterol 102 2007 2047 2056 quiz 2057
108. M.H. Wilcox, L. Mooney, and R. Bendall A case-control study of community-associated Clostridium difficile infection J Antimicrob Chemother 62 2008 388 396
109. M.M. Nerandzic, M.J. Pultz, and C.J. Donskey Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection Antimicrob Agents Chemother 53 2009 4133 4137
110. L. Grimelius, H. Johansson, and G. Lundqvist The parathyroid glands in experimentally induced hypergastrinemia in the rat Scand J Gastroenterol 12 1977 739 744
111. R. Gagnemo-Persson, R. Hakanson, and F. Sundler Growth of the parathyroid glands in omeprazole-treated chickens Scand J Gastroenterol 29 1994 493 497
112. R. Gagnemo-Persson, and A. Samuelsson Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake Calcif Tissue Int 61 1997 210 215
113. K. Mizunashi, Y. Furukawa, and K. Katano Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans Calcif Tissue Int 53 1993 21 25
114. R. Carmel, K.H. Lau, and D.J. Baylink Cobalamin and osteoblast-specific proteins N Engl J Med 319 1988 70 75
115. K.L. Stone, D.C. Bauer, and D. Sellmeyer Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study [see comment] J Clin Endocrinol Metabol 89 2004 1217 1221
116. K.L. Tucker, M.T. Hannan, and N. Qiao Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study J Bone Miner Res 20 2005 152 158
117. A.H. Kang, and R.L. Trelstad A collagen defect in homocystinuria J Clin Invest 52 1973 2571 2578
118. B. Lubec, S. Fang-Kircher, and T. Lubec Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria Biochim Biophys Acta 1315 1996 159 162
119. R.R. McLean, P.F. Jacques, and J. Selhub Homocysteine as a predictive factor for hip fracture in older persons N Engl J Med 350 2004 2042 2049 [see comment]
120. J.B. van Meurs, R.A. Dhonukshe-Rutten, and S.M. Pluijm Homocysteine levels and the risk of osteoporotic fracture N Engl J Med 350 2004 2033 2041 [see comment]
121. R.R. McLean, P.F. Jacques, and J. Selhub Plasma B vitamins, homocysteine and their relation with bone loss and hip fracture in elderly men and women J Clin Endocrin Metab 93 2008 2206 2212
122. Y. Sato, Y. Honda, and J. Iwamoto Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial JAMA 293 2005 1082 1088 [see comment] [erratum appears in JAMA. 2006;296:396]
123. P. Vestergaard, L. Rejnmark, and L. Mosekilde Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture Calcif Tissue Int 79 2006 76 83
124. Y.-X. Yang, J.D. Lewis, and S. Epstein Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2006 2947 2953
125. L.E. Targownik, L.M. Lix, and C.J. Metge Use of proton pump inhibitors and risk of osteoporosis-related fractures CMAJ 179 2008 319 326 [see comment]
126. F. De Vries, A. Cooper, and R. Logan Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonates alone Osteoporosis Int 18 2007 S261
127. J.A. Kaye, and H. Jick Proton pump inhibitor use and risk of hip fractures in patients without major risk factors Pharmacotherapy 28 2008 951 959
128. L.E. Targownik, L.M. Lix, and S. Leung Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss Gastroenterology 138 2010 896 904
129. H. Larsson, E. Carlsson, and H. Mattsson Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation Studies with omeprazole and ranitidine in intact and antrectomized rats Gastroenterology 90 1986 391 399
130. E. Carlsson, H. Larsson, and H. Mattsson Pharmacology and toxicology of omeprazole - with special reference to the effects on the gastric mucosa Scand J Gastroenterol Suppl 118 1986 31 38
131. D. Gillen, A.A. Wirz, and J.E. Ardill Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status Gastroenterology 116 1999 239 247
132. D. Gillen, A.A. Wirz, and K.E.L. McColl Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment Gastroenterology 126 2004 980 988 [Erratum appears in Gastroenterology. 2004;127:694]
133. C. Reimer, B. Sondergaard, and L. Hilsted Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy Gastroenterology 137 2009 80 87
134. A. Niklasson, L. Lindstrom, and M. Simren Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial Am J Gastroenterol 105 2010 1531 1537
135. D.C. Metz, B.L. Pilmer, and C. Han Lack of acid and symptom rebound after withdrawal of 4 to 8 weeks of dexlansoprazole MR or lansoprazole therapy (abstr) Gastroenterology 138 Issue 5, Supplement 1 2010 S-652
136. E. Rey, F. Rodriguez-Artalejo, and M.A. Herraiz Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study Am J Gastroenterol 102 2007 2395 2400
137. A. Ruigomez, L.A. Garcia Rodriguez, and C. Cattaruzzi Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes Am J Epidemiol 150 1999 476 481
138. O. Diav-Citrin, J. Arnon, and S. Shechtman The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study Aliment Pharmacol Ther 21 2005 269 275
139. B.A. Kallen Use of omeprazole during pregnancyno hazard demonstrated in 955 infants exposed during pregnancy Eur J Obstet Gynecol Reprod Biol 96 2001 63 68
140. S. Nikfar, M. Abdollahi, and M.E. Moretti Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis Dig Dis Sci 47 2002 1526 1529
141. A. Lalkin, R. Loebstein, and A. Addis The safety of omeprazole during pregnancy: a multicenter prospective controlled study Am J Obstet Gynecol 179 1998 727 730 (Pubitemid 28447254)
142. G.L. Nielsen, H.T. Sorensen, and A.M. Thulstrup The safety of proton pump inhibitors in pregnancy Aliment Pharmacol Ther 13 1999 1085 1089
143. A.D. Rhim, J.R. Hardy, and K. Haynes Maternal use of proton pump inhibitors during pregnancy is associated with an increased risk for cardiac birth defects: analysis of 208,951 pregnancies from the GPRD/THIN database (abstr) Gastroenterology 138 2010 S-63
144. E. Alexopoulos Drug-induced acute interstitial nephritis Ren Fail 20 1998 809 819
145. J. Rossert Drug-induced acute interstitial nephritis Kidney Int 60 2001 804 817
146. S.J. Ruffenach, M.S. Siskind, and Y.H. Lien Acute interstitial nephritis due to omeprazole Am J Med 93 1992 472 473
147. F. Sierra, M. Suarez, and M. Rey Systematic review: proton pump inhibitor-associated acute interstitial nephritis Aliment Pharmacol Ther 26 2007 545 553
148. I.J. Simpson, M.R. Marshall, and H. Pilmore Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases Nephrology 11 2006 381 385
149. L. Harmark, H.E. van der Wiel, and M.C.H. de Groot Proton pump inhibitor-induced acute interstitial nephritis Br J Clin Pharmacol 64 2007 819 823
150. R.P. Myers, K. McLaughlin, and D.J. Hollomby Acute interstitial nephritis due to omeprazole Am J Gastroenterol 96 2001 3428 3431
151. D.L. Bhatt, J. Scheiman, and N.S. Abraham ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use Am J Gastroenterol 103 2008 2890 2907
152. S.J. Spechler, E. Lee, and D. Ahnen Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial JAMA 285 2001 2331 2338